NCT00035256已完成4 期
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 330
- 试验地点
- 6
- 主要终点
- The study is designed to compare the effect of 1 year of raloxifene treatment with the effect of placebo on maintaining teriparatide-induced increases in spine and hip BMD.
研究概览
简要总结
The purpose of this study is to determine whether the increase in spine bone mineral density that has been generally observed in previous clinical studies involving the study drug can be maintained or even increased if followed with raloxifene HCl. All qualifying study participants will receive the study drug followed by treatment with raloxifene HCl or placebo. All study participants will receive raloxifene HCl in the third phase of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 55 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Must be diagnosed with osteoporosis
- •Must be female, age 55 through 80
- •Must be at least 5 years postmenopausal
- •Must be free of other severe or chronically disabling conditions
- •Must be able to properly use injection device.
排除标准
- •Must not have bone diseases other than osteoporosis
- •Must not have history of certain cancers
- •Must not have certain medical diseases (inflammatory bowel disease, malabsorption syndrome, kidney or bladder stones, venous thrombi or emboli, recent vaginal bleeding due to unknown causes)
- •Must not have treatment with particular medications (warfarin, estrogens, androgens, steroids, calcitonins, fluorides, biphosphonates)
- •Must not have known allergy to the study agent or raloxifene HCl
结局指标
主要结局
The study is designed to compare the effect of 1 year of raloxifene treatment with the effect of placebo on maintaining teriparatide-induced increases in spine and hip BMD.
次要结局
- An open-label treatment phase will extend the study for 1 year beyond the primary endpoint. During this final year of the study all patients will receive raloxifene.
- The purpose of lengthening is to assess the differences in response to raloxifene when it is administered immediately following versus 1 year after(with and without a washout period) withdrawal from teriparatide.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Study of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisOsteoporosis, Post-MenopausalNCT00532207Eli Lilly and Company50
已完成
不适用
Combination therapy of Eldecalcitol with Risedronate on Aromatase inhibitor treated post-operative Mammary carcinoma In the prevention of bone QUality and quantity Exacerbation (CERAMIQUE) randomized trialSecondary osteoporosisJPRN-UMIN000008286Osaka City University Graduate School of Medicine200
已完成
3 期
Effects of Arzoxifene on Bone Mass and the UterusPostmenopausal Bone LossNCT00085956Eli Lilly and Company300
已完成
3 期
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)Osteoporosis, PostmenopausalNCT00389740Organon and Co400
已完成
4 期
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone ResorptionPostmenopausal OsteoporosisNCT01750086Massachusetts General Hospital27